Aclaris Therapeutics (ACRS) Reports Q4 Loss of $0.28/Share
Tweet
Share
E-mailGet Alerts ACRS Hot Sheet
Join SI Premium – FREE
Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.28), versus ($1.76) reported last year.
For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fox upgraded to overweight as Roku deal, ad strength lift outlook
- Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
- Workhorse Group (WKHS) Misses Q2 EPS by 77c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
